Thiemann, A., Holsteyns, F., Cairs, C
The oral segment is expected to grow rapidly with CAGR of 22.9% during the forecast period due to its convenience and noninvasive administration, which improves patient observation
Now, you might be wondering about variations
The pharmacy benefit manager Prime Therapeutics published an analysis last summer that highlights this ongoing challenge with respect to the real-world effectiveness over time of the GLP-1 drugs used to treat obesity: Most overweight or obese patients without diabetes stop treatment within the first few years
To address this gap, future studies should adopt cell-type-specific and temporally controlled genetic or pharmacologic interventions to clarify whether the IGF family plays predominantly protective or pathogenic roles under different contexts
Folks are anecdotally getting better sleep and having improved heart rate variability values